CN115697401A - 离体γδT细胞群体 - Google Patents

离体γδT细胞群体 Download PDF

Info

Publication number
CN115697401A
CN115697401A CN202180028136.1A CN202180028136A CN115697401A CN 115697401 A CN115697401 A CN 115697401A CN 202180028136 A CN202180028136 A CN 202180028136A CN 115697401 A CN115697401 A CN 115697401A
Authority
CN
China
Prior art keywords
seq
sequence
cells
antibody
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028136.1A
Other languages
English (en)
Chinese (zh)
Inventor
O·努斯鲍默
O·波利亚科娃
A·黑戴
P·万图
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gamade Therapy Co ltd
Original Assignee
Gamade Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamade Therapy Co ltd filed Critical Gamade Therapy Co ltd
Publication of CN115697401A publication Critical patent/CN115697401A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180028136.1A 2020-02-24 2021-02-24 离体γδT细胞群体 Pending CN115697401A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies
GB2002581.3 2020-02-24
PCT/GB2021/050460 WO2021171003A1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations

Publications (1)

Publication Number Publication Date
CN115697401A true CN115697401A (zh) 2023-02-03

Family

ID=70108379

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180028136.1A Pending CN115697401A (zh) 2020-02-24 2021-02-24 离体γδT细胞群体
CN202180030584.5A Pending CN115461369A (zh) 2020-02-24 2021-02-24 新型抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180030584.5A Pending CN115461369A (zh) 2020-02-24 2021-02-24 新型抗体

Country Status (17)

Country Link
US (2) US20230159638A1 (https=)
EP (3) EP4591882A3 (https=)
JP (2) JP2023516925A (https=)
KR (2) KR20220145894A (https=)
CN (2) CN115697401A (https=)
AU (2) AU2021228266A1 (https=)
BR (2) BR112022016894A2 (https=)
CA (2) CA3168973A1 (https=)
CL (1) CL2022002296A1 (https=)
CO (2) CO2022013542A2 (https=)
EC (1) ECSP22074030A (https=)
GB (1) GB202002581D0 (https=)
IL (2) IL295852A (https=)
MX (2) MX2022010383A (https=)
PE (1) PE20230438A1 (https=)
WO (2) WO2021171002A1 (https=)
ZA (1) ZA202209699B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667501A (zh) * 2020-05-12 2023-01-31 伽玛德治疗有限公司 用于分离γδT细胞的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249605A (zh) * 2014-11-17 2017-10-13 阿迪塞特生物股份有限公司 工程化的γδT细胞
CN108350428A (zh) * 2015-06-09 2018-07-31 淋巴-淋巴细胞活化技术公司 用于生产TCRγδ+T细胞的方法
CN110072533A (zh) * 2016-05-12 2019-07-30 阿迪塞特生物股份有限公司 选择性扩增γδT细胞群的方法及其组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3145523A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249605A (zh) * 2014-11-17 2017-10-13 阿迪塞特生物股份有限公司 工程化的γδT细胞
CN108350428A (zh) * 2015-06-09 2018-07-31 淋巴-淋巴细胞活化技术公司 用于生产TCRγδ+T细胞的方法
CN110072533A (zh) * 2016-05-12 2019-07-30 阿迪塞特生物股份有限公司 选择性扩增γδT细胞群的方法及其组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AW LANGERAK等: "Immunophenotypic and immunogenotypic characteristics of TCRγδ+ T cell acute lymphoblastic leukemia", 《LEUKEMIA》, vol. 13, 1 February 1999 (1999-02-01), pages 206 - 214 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667501A (zh) * 2020-05-12 2023-01-31 伽玛德治疗有限公司 用于分离γδT细胞的方法
CN115667501B (zh) * 2020-05-12 2025-09-16 伽玛德治疗有限公司 用于分离γδT细胞的方法

Also Published As

Publication number Publication date
CO2022013542A2 (es) 2022-10-11
BR112022016671A2 (pt) 2022-11-16
CO2022013633A2 (es) 2023-02-16
JP2023514437A (ja) 2023-04-05
AU2021228266A1 (en) 2022-10-13
EP4591882A2 (en) 2025-07-30
EP4591882A3 (en) 2025-10-15
ECSP22074030A (es) 2022-10-31
CA3172340A1 (en) 2021-09-02
MX2022010239A (es) 2022-11-14
PE20230438A1 (es) 2023-03-08
MX2022010383A (es) 2022-09-05
IL295852A (en) 2022-10-01
WO2021171002A1 (en) 2021-09-02
EP4110387A1 (en) 2023-01-04
CN115461369A (zh) 2022-12-09
AU2021225390A1 (en) 2022-09-22
BR112022016894A2 (pt) 2023-04-04
WO2021171003A1 (en) 2021-09-02
CA3168973A1 (en) 2021-09-02
EP4110813A1 (en) 2023-01-04
CL2022002296A1 (es) 2023-03-31
US20230090901A1 (en) 2023-03-23
EP4110387B1 (en) 2025-05-21
KR20220145894A (ko) 2022-10-31
JP2023516925A (ja) 2023-04-21
US20230159638A1 (en) 2023-05-25
IL295696A (en) 2022-10-01
GB202002581D0 (en) 2020-04-08
ZA202209699B (en) 2024-12-18
KR20220164473A (ko) 2022-12-13

Similar Documents

Publication Publication Date Title
CN113039205B (zh) 靶向cll1的抗体及其应用
JP7764364B2 (ja) エクスビボγδ Ｔ細胞集団
AU2016339832B2 (en) Antibody agents specific for human CD19 and uses thereof
KR101566539B1 (ko) 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
CN114514245A (zh) 新颖的抗TCRδ可变1抗体
KR20180132751A (ko) Bcma 결합 분자 및 그의 사용 방법
CN115697401A (zh) 离体γδT细胞群体
CN116096863A (zh) 免疫疗法组合物
CN112839963B (zh) 新型癌症免疫治疗抗体组合物
US20240409625A9 (en) Engineered dual binding antibodies and uses thereof
HK40084452A (en) Novel antibodies
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака
EA052465B1 (ru) Популяции гамма-дельта т-клеток ex vivo
HK40075692A (en) Novel anti-tcr delta variable 1 antibodies
HK40130434A (en) Ex vivo gamma delta t cell populations
CN117616043A (zh) 经工程化的双重结合抗体及其用途
HK40059258A (en) Transgenic rabbit with common light chain
HK40086246B (en) Ex vivo gamma delta t cell populations
HK40086246A (en) Ex vivo gamma delta t cell populations
EA050989B1 (ru) Популяции гамма-дельта т-клеток ex vivo
HK40047112B (en) Novel cancer immunotherapy antibody compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination